Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous NK cell therapy (Southwest Hospital)
- Development stage
- Unknown
- Lead developer
- Southwest Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous NK cell therapy (Southwest Hospital) is an investigational adoptive cell immunotherapy developed for the treatment of advanced non-small cell lung cancer (NSCLC). The therapeutic process involves isolating natural killer (NK) cells from a patient's own peripheral blood, followed by ex vivo expansion and activation to enhance their cytotoxic potential. Once re-infused into the patient, these activated NK cells are capable of identifying and eliminating malignant cells through the release of cytotoxic granules containing perforin and granzymes, as well as through the induction of apoptosis via death receptor pathways. In clinical research conducted at Southwest Hospital in China, this cell therapy is evaluated in combination with standard platinum-based chemotherapy (paclitaxel and carboplatin) to investigate potential synergistic effects in improving objective response rates and progression-free survival in patients with advanced NSCLC.
- Other names
- NK cellsNatural killer cell infusionAutologous NK cells
02
Targets
ULBP1 (UL16-binding protein 1)
Beyond the preview
Go deeper on Autologous NK cell therapy (Southwest Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous NK cell therapy (Southwest Hospital).